Chi Longevity.

What Chi Longevity actually is

Asia’s most academically credentialed longevity practice. Founded in March 2023 in Singapore by Professor Andrea Maier — Internal Medicine specialist and Geriatrician with a substantial academic record at the National University of Singapore and the University of Melbourne — and Dr. Tuck Wah Soong. Chi operates across three Singapore sites: Camden Medical Centre, Four Seasons Hotel Singapore, and Sparkd, a dedicated cognitive and physical performance training facility.

The differentiator is the academic anchor. Most longevity clinics are founded by entrepreneur-clinicians or by medical directors with private-practice backgrounds. Maier is a published geroscientist whose academic work informs the clinical practice the way the brand says it does — which is unusual in this category and worth crediting.

The Maier Method

Chi’s modular programme structure is well-designed: seven specialised programmes (Gene Insights for nutrition, Biological Age Reveal, Body Recomposition, Glucose Navigator, Gut Health, Sleep & Stress, Physical Performance) priced from SGD 1,800 each. Readers can buy the workup that addresses a specific question rather than committing to a packaged tier they may not need.

A full longevity assessment is the integrated intake: genetic and epigenetic clocks, comprehensive metabolic and endocrine panel, cardiovascular risk analysis, neuroimaging where indicated, microbiome, functional performance. Pricing is modular and the indicative figure for a full intake is materially higher than the entry programme.

Where it earns the score

Three structural reasons.

The academic anchor. Maier’s geriatric and geroscience background, peer-reviewed publication record, and academic affiliations are unusual in this field. The clinical practice reflects the academic posture: emerging biomarkers are framed as biomarkers, not as anti-ageing tools.

The modular structure. Buying a specialised programme is a lower-commitment way to sample the practice than committing to an annual membership. We rate this respect for reader autonomy.

Singapore as a hub. For Asian readers, direct flight access, English-language medicine, regulatory clarity, and Maier’s clinical reputation make Chi the credible regional choice in a way that no other Asian clinic currently matches.

Where it falls short

Two honest caveats.

The specialised programmes do bundle diagnostics with intervention design — the protocol that follows your data is recommended by the same clinic that ran the workup. Maier’s clinical group is academically posed, not commercially aggressive, so we rate the conflict pressure as limited rather than structural. But the geometry exists.

The clinic is young. March 2023 means the longitudinal data the practice itself is collecting is still early-stage. The published methodology benefits from Maier’s academic record, not yet from the practice’s own outcomes.

The verdict

For the Asian reader looking for a credible longevity clinic with an academic anchor, Chi is currently the regional leader. We rank it slightly behind YEARS, Biograph, Early Medical and Human Longevity not because the medicine is weaker but because the model bundles intervention slightly more tightly than those four — and the practice has had less time to demonstrate longitudinal outcomes.

The academic anchor is rare in this category. Where it exists, it earns weight.